Acquisition announced
As filed · Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of Kenalog®, a branded commercial injectable product
What happened
FactPiramal Pharma Limited's subsidiary, Piramal Critical Care B.V., has entered into an agreement to acquire Kenalog® and its associated brands from Bristol-Myers Squibb Company for an upfront payment of US$ 35 million, with potential additional payments of up to US$ 65 million based on certain milestones. The acquisition aims to enhance the company's distribution network and broaden its product portfolio in the US, Europe, and Asia Pacific. This transaction is not classified…
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
Watch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
Evidence
How CapitSignal classified this
- Reasoning:
- ACQUISITION base 74; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%